HPV genotyping and potential progression markers in cervical intraepithelial neoplasia : Clinical and diagnostic impact

Detta är en avhandling från Stockholm : Karolinska Institutet, Department of Clinical Sciences

Sammanfattning: The aim of this thesis is to identify clinically useful early molecular markers to predict progression to carcinoma in women with preinvasive lesions of the cervix, for the purpose of improving care of these women and enabling more individualized treatment. In order to define the human papillomavirus (HPV) types in minor cytological abnormalities, 343 liquid-based cytology (LBC) samples with atypical squamous cells of uncertain significance (ASCUS) and with low-grade squamous intraepithelial lesions (LSIL) were genotyped using Linear Array. We found high-risk (HR-) HPV in 71% of LSIL and 49% of ASCUS cases (p<0.001). HR-HPV prevalence was similar in LSIL and ASCUS cases among women over 25 years. Younger (<25 years) and older (>50 years) women had higher prevalence of HR-HPV and multiple infections (p=0.01). HPV16 was found in 23% and HPV18 in 10% (p<0.001) of HPV-positive women. To test the utility of HPV genotyping in post-surgical monitoring, we genotyped cones of 90 women and follow-up samples after conization, and evaluated cytological results from two consecutive visits. Margin status and presence of CIN3+ in the cone were poor predictors of treatment outcome (sensitivity <50%). Presence of any probable HR/HR-HPV (18 types) predicted all residual high-grade SIL/ cervical intraepithelial neoplasia (CIN) 2 or worse with 73% specificity. Consideration of only 13 HR-HPV types showed equal sensitivity, but higher specificity (86%, p<0.01). True persistent infection detected high-grade residual disease with 60% sensitivity and 95% specificity, resulting in a positive predictive value (PPV) of 43%. We also assessed the utility of p16INK4a immunocytochemical detection of dysplastic cells in 118 samples from patients referred for further testing because of cytological abnormality. Intensity of p16INK4a staining correlated well with CIN grade, particularly when diagnosis was based on simultaneous routine cytology (p<0.001, Rho 0.70). Immunostaining for p16INK4a was feasible in clinical practice and helped to distinguish premalignant cells from reactive cells. To map local immune responses to HPV, we analyzed expression of several immune markers using real -time RT-PCR in cervical biopsies from 24 female volunteers who had been genotyped for HPV. No difference between the 11 HPV-positive and 13 HPV-negative women was found for mRNA expression of any of the immune markers. Surprisingly, levels of the B cell marker CD19 were elevated among women using hormonal contraception (p<0.05). HPV genotyping revealed age-dependent patterns of HPV infections in LSIL and ASCUS cases. We propose triage HPV testing of LSIL after 30 years of age. Genotyping after conization substantially increased PPV, but with loss in sensitivity. General HR-HPV testing will identify all recurrent or residual high-grade CIN. Demonstration of p16INK4a accumulation in the cell nucleus is a simple way to enhance presence of dysplastic cells and to distinguish these from reactive atypia. HPV infection per se does not evoke local immune response as measured by semi-quantitative RT-PCR. Hormonal contraception may influence B cell activity in the cervix. Further studies are needed to identify potential progression markers.

  HÄR KAN DU HÄMTA AVHANDLINGEN I FULLTEXT. (följ länken till nästa sida)